Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate

123 Background: Restaging with PET-CT in biochemical recurrent prostate cancer after prostatectomy shows a higher frequency of (false) negative cases compared to restaging after EBRT. It is uncertain if this reflects low volume of disease and/or low grade as biopsies fail to prove recurrent cancer in 50% of cases. We followed the clinical course of men with recurrent prostate cancer (PCa) after radical prostatectomy and investigated treatment and survival. PET-CT data were correlated with clinical data, PSA kinetics and disease specific and overall survival. We also studied relative survival comparing an age matched group from the Central Dutch Statistical Office (CBS). Methods: 64 patients underwent 11C-Choline PET-CT on PSA relapse. All patients were initially treated with radical prostectomy and reached PSA nadir of <0.1ng/mL. Recurrent disease was defined as PSA <0.4ng/mL after nadir. Patients were either treated with watchful waiting, adjuvant radiotherapy and/ or androgen deprivation therapy based on individual assesments by the treating urologists. Chi-square, log-rank and Mann-Whitney-U tests were used to study this population Results: The 64 patients had median PSA of 1.4ng/mL. Median follow-up period of patients was 50 (6–124) months. Ten patients died during the course of follow-up of which 5 due to metastasized PCa. No significant differences were seen in age, time to recurrence, total PSA at recurrence and PET-CT results. Patients with abnormal PET had higher PSAVel (median 3.09 ng/mL/yr vs 10.17, p= 0.002) and and shorter PSADT (med 4.83 mo vs 0.53, p= 0.016). Median time to treatment was significantly lower in the PET-CT negative group. Age of patients at death from the whole group did not differ from the age of death in an age matched group. Disease specific survival was significantly higher in the PET-CT negative group (p0.05). Conclusions: A negative 11C-Choline PET-CT correlated with a higher disease specific survival and a lower treatment rate. Overall survival of the group was equal to the age matched cohort. No significant financial relationships to disclose.

Download Full-text

Neoadjuvant hormone therapy before radical prostatectomy does not improve disease-specific survival

Current Urology Reports ◽

10.1007/s11934-000-0028-y ◽

2000 ◽

Vol 1 (1) ◽

pp. 7-8 ◽

Cited By ~ 1

Author(s):

Mitchell S. Steiner

Keyword(s):

Radical Prostatectomy ◽

Hormone Therapy ◽

Disease Specific Survival ◽

Disease Specific

Download Full-text

Increased HSF1 expression predicts shorter disease-specific survival of prostate cancer patients following radical prostatectomy

Oncotarget ◽

10.18632/oncotarget.25756 ◽

2018 ◽

Vol 9 (58) ◽

pp. 31200-31213 ◽

Cited By ~ 10

Author(s):

Johanna K. Björk ◽

Ilmari Ahonen ◽

Tuomas Mirtti ◽

Andrew Erickson ◽

Antti Rannikko ◽

...

Keyword(s):

Prostate Cancer ◽

Radical Prostatectomy ◽

Cancer Patients ◽

Disease Specific Survival ◽

Disease Specific

Download Full-text

Radical Prostatectomy Versus Observation for Localized Prostate Cancer

50 Studies Every Urologist Should Know ◽

10.1093/med/9780190655341.003.0007 ◽

2021 ◽

pp. 37-42

Author(s):

Philipp Dahm

Keyword(s):

Prostate Cancer ◽

Radical Prostatectomy ◽

Watchful Waiting ◽

Specific Antigen ◽

Localized Prostate Cancer ◽

Disease Specific Survival ◽

Long Term Follow Up ◽

Disease Specific

This chapter provides a summary of the landmark PIVOT trial that randomized men with clinically localized prostate cancer from the early prostate-specific antigen (PSA) era to radical prostatectomy versus watchful waiting. Based on long-term follow-up, the study found that surgery provided only small reductions in disease-specific survival but caused substantial side effects. It suggested that many men with clinically localized prostate cancer fare well with watchful waiting.

Download Full-text

P155 Loss of PTEN expression together with ERG overexpression leads to shorter disease-specific survival in prostate cancer after radical prostatectomy

European Urology Supplements ◽

10.1016/s1569-9056(14)61378-6 ◽

2014 ◽

Vol 13 (5) ◽

pp. 167-168

Author(s):

K. Lahdensuo ◽

A. Erickson ◽

J. Lundin ◽

M. Lundin ◽

S. Nordling ◽

...

Keyword(s):

Prostate Cancer ◽

Radical Prostatectomy ◽

Pten Expression ◽

Disease Specific Survival ◽

Disease Specific

Download Full-text

Microvessel density as a prognostic indicator of prostate cancer: A systematic review and meta-analysis

Open Medicine ◽

10.1515/med-2020-0235 ◽

2021 ◽

Vol 16 (1) ◽

pp. 882-891

Author(s):

Guangui Feng ◽

Kai Wang ◽

Zhao Jiang

Keyword(s):

Prostate Cancer ◽

Microvessel Density ◽

Fixed Effects ◽

Meta Analysis ◽

Library Science ◽

Cochrane Library ◽

Recurrence Free Survival ◽

Disease Specific Survival ◽

Free Survival ◽

Disease Specific

Abstract The aim of this study is to evaluate prognostic and therapeutic implications of microvessel density (MVD) in the recurrence-free survival (RFS), disease-specific survival (DSS), and overall survival (OS) in prostate cancer (PCa). As of April 2019, EMBASE, PubMed, Cochrane Library, Science Direct/Elsevier, MEDLINE, and CNKI are used for systematic literature retrieval to investigate the correlation between MVD and PCa. Meta-analysis was performed using Review Manager and Stata software. Combined hazard ratio (HR) was identified with 95% confidence intervals (95% CI) in a random or fixed effects model. Thirteen studies were identified in this article. Of which, 8 studies analyzed for the recurrence-free survival (2,399 patients) demonstrated that MVD significantly elevated in the poor recurrence-free survival (HR 2.57, 95% CI 2.21–2.97). Other 2 eligible studies (330 patients) with 3 data sets for the MVD-OS analysis and the pooled HR (HR 1.70, 95% CI 1.27–2.28) suggested a weak risk of overall death rate in patients with high-MVD levels. The last 3 studies for disease-specific survival (220 patients) suggested that the association with high MVD and disease-specific survival may not have statistically significance (HR 1.32, 95% CI 0.49–3.56). This study suggests that high intratumoral MVD appears a significant progenitor for poor recurrence-free survival of PCa.

Download Full-text